Form 4: Biodesix CAO Vazquez Sells Shares for Tax

Biodesix Chief Accounting Officer Chris Vazquez sold 211 shares of common stock to cover taxes following the vesting of restricted stock units.

Summary

• Chris Vazquez, Chief Accounting Officer of Biodesix Inc. (BDSX), acquired 563 shares of common stock on February 20, 2026, through the vesting of Restricted Stock Units (RSUs).
• Following this acquisition, Vazquez's direct beneficial ownership increased to 1,797 shares.
• On February 23, 2026, Vazquez sold 211 shares of Biodesix common stock at a weighted average price of $12.7756 per share.
• This sale was an automatic transaction to cover tax obligations arising from the RSU vesting.
• After the sale, Vazquez's direct beneficial ownership stands at 1,586 shares.
• All reported numbers have been adjusted to reflect a one-for-twenty reverse stock split effective September 15, 2025.
• The RSUs vest in four equal annual installments starting February 20, 2025, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine insider transaction related to executive compensation and tax obligations, with no significant positive or negative implications for the company's operational or financial performance.

Positives

• Vesting of 563 Restricted Stock Units (RSUs) indicates continued employment and compensation for the Chief Accounting Officer.
• The acquisition of shares through RSU vesting increases the officer's direct stake in the company before the tax-related sale.

Negatives

• The sale of 211 shares, even for tax purposes, reduces the direct beneficial ownership of the Chief Accounting Officer.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those for tax purposes following RSU vesting, are common across all industries and typically do not reflect a change in management's outlook on the company's prospects. This filing is specific to an individual's compensation and tax planning rather than broader industry trends.

Comparison to Industry Standards

• StockSavvy.ai observes that tax-related sales upon RSU vesting are a standard practice for executives across publicly traded companies, including those in the biotechnology and diagnostics sectors.
• This transaction aligns with typical compensation structures and tax management strategies seen at companies comparable to Biodesix, such as Exact Sciences (EXAS) or Guardant Health (GH), where executives often sell a portion of vested equity to cover statutory tax withholdings.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, small-scale insider transaction for tax purposes.
• Employees: No direct impact on general employees.

Next Steps

• Remaining Restricted Stock Units (RSUs) will continue to vest in three more equal annual installments from February 20, 2025, subject to Chris Vazquez's continued service with Biodesix.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Accounting Officer sold shares to cover taxes upon RSU vesting. Such transactions are common and generally do not indicate a change in the company's fundamentals or future prospects. Therefore, a 'hold' recommendation is appropriate as this specific filing provides no new information to alter an existing investment thesis.

Keywords

Biodesix, BDSX, Chris Vazquez, Chief Accounting Officer, Form 4, Insider Transaction, Restricted Stock Units, RSU vesting, Stock Sale, Tax Sale, Reverse Stock Split